Index Entries

Adrian R. Martineau, David A. Jolliffe, Richard L. Hooper, Lauren Greenberg, John F. Aloia, Peter Bergman, Gal Dubnov-Raz, Susanna Esposito, Davaasambuu Ganmaa, Adit A. Ginde, Emma C. Goodall, Cameron C. Grant, Christopher J. Griffiths, Wim Janssens, Ilkka Laaksi, Semira Manaseki-Holland, David Mauger, David R. Murdoch, Rachel Neale, Judy R. Rees, Steve Simpson Jr., Iwona Stelmach, Geeta Trilok Kumar, Mitsuyoshi Urashima, and Carlos A. Camargo Jr.
February 15, 2017
British Medical Journal
Queen Mary University of London

Results: 25 eligible randomised controlled trials (total 11,321 participants, aged 0 to 95 years) were identified. IPD were obtained for 10,933 (96.6%) participants. Vitamin D supplementation reduced the risk of acute respiratory tract infection among all participants… The body of evidence contributing to these analyses was assessed as being of high quality…

Conclusions and policy implications: Our study reports a major new indication for vitamin D supplementation: the prevention of acute respiratory tract infection. We also show that people who are very deficient in vitamin D and those receiving daily or weekly supplementation without additional bolus doses experienced particular benefit. Our results add to the body of evidence supporting the introduction of public health measures such as food fortification to improve vitamin D status, particularly in settings where profound vitamin D deficiency is common.”

document
COVID-19,medical treatments,nutraceuticals,vitamin D